Patents by Inventor Tapan Sanghvi
Tapan Sanghvi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11485739Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-A or I-B: wherein the variables are as defined herein.Type: GrantFiled: August 17, 2020Date of Patent: November 1, 2022Assignee: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Jean-Damien Charrier, Christopher John Davis, Damien Fraysse, Gorka Etxebarria I Jardi, Simon Pegg, Francoise Pierard, Joanne Pinder, John Studley, Carl Zwicker, Tapan Sanghvi, Michael Waldo, Ales Medek, David Matthew Shaw, Maninder Panesar, Yuegang Zhang, Naziha Alem
-
Publication number: 20220265765Abstract: The present invention provides, among other things, improved therapeutic compositions comprising a C3 fusion protein and methods of making and using the same. In particular, the present invention provides improved methods for the treatment of spinal cord injury and other CNS trauma and/or facilitate axon growth or other tissue repair.Type: ApplicationFiled: May 6, 2022Publication date: August 25, 2022Inventors: Ricardo BORJAS, Mark FLEMING, Mei HUANG, Mayur JAIN, Tapan SANGHVI, Kumkum SAXENA, Amaris TORRES-DELGADO, Ping YIN, Lisa MCKERRACHER, Elizabeth RYU
-
Patent number: 11324802Abstract: The present invention provides, among other things, improved therapeutic compositions comprising a C3 fusion protein and methods of making and using the same. In particular, the present invention provides improved methods for the treatment of spinal cord injury and other CNS trauma and/or facilitate axon growth or other tissue repair.Type: GrantFiled: May 30, 2018Date of Patent: May 10, 2022Assignee: BioAxone BioSciences, Inc.Inventors: Ricardo Borjas, Mark Fleming, Mei Huang, Mayur Jain, Tapan Sanghvi, Kumkum Saxena, Amaris Torres-Delgado, Ping Yin, Lisa McKerracher, Elizabeth Ryu
-
Publication number: 20210138035Abstract: The present invention provides, among other things, improved therapeutic compositions comprising a C3 fusion protein and methods of making and using the same. In particular, the present invention provides improved methods for the treatment of spinal cord injury and other CNS trauma and/or facilitate axon growth or other tissue repair.Type: ApplicationFiled: May 30, 2018Publication date: May 13, 2021Inventors: Ricardo BORJAS, Mark FLEMING, Mei HUANG, Mayur JAIN, Tapan SANGHVI, Kumkum SAXENA, Amaris TORRES-DELGADO, Ping YIN, Lisa MCKERRACHER, Elizabeth RYU
-
Publication number: 20210032255Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-A or I-B: wherein the variables are as defined herein.Type: ApplicationFiled: August 17, 2020Publication date: February 4, 2021Inventors: Jean-Damien CHARRIER, Christopher John DAVIS, Damien FRAYSSE, Gorka ETXEBARRIA I JARDI, Simon PEGG, Francoise PIERARD, Joanne PINDER, John STUDLEY, Carl ZWICKER, Tapan SANGHVI, Michael WALDO, Ales MEDEK, David Matthew SHAW, Maninder PANESAR, Yuegang ZHANG, Naziha ALEM
-
Publication number: 20210008072Abstract: A pharmaceutical composition comprises: a) 5 wt % to 95 wt % of a HCl salt of Compound (1).xH2O by the weight of the pharmaceutical composition, wherein x is from 0 to 3; and b) 5 wt % to 95 wt % of a filler by the weight of the pharmaceutical composition. Another pharmaceutical composition comprises: a) 1 mg/mL to 20 mg/mL of Compound (1) in water; and b) 0.01 M to 0.1 M of a pharmaceutically acceptable pH modifier. A method of preparing a pharmaceutical composition, comprising providing a mixture of Compound (1) that includes the HCl salt of Compound (1).xH2O and the filler. Another method of preparing a pharmaceutical composition comprises mixing the HCl salt of Compound (1).xH2O and the pH modifier to form 1 mg/mL to 20 mg/mL of Compound (1) in water. Methods of reducing the amount of influenza viruses, inhibiting the replication of influenza viruses, and treating influenza each independently employ such pharmaceutical compositions.Type: ApplicationFiled: September 30, 2020Publication date: January 14, 2021Inventors: Eric Arthur Simone, Tapan Sanghvi, Alamelu Banda, Katherine Stavropoulos
-
Patent number: 10815239Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-A or I-B: wherein the variables are as defined herein.Type: GrantFiled: November 15, 2018Date of Patent: October 27, 2020Assignee: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Jean-Damien Charrier, Christopher John Davis, Damien Fraysse, Gorka Etxebarria I Jardi, Simon Pegg, Francoise Pierard, Joanne Pinder, John Studley, Carl Zwicker, Tapan Sanghvi, Michael Waldo, Ales Medek, David Matthew Shaw, Maninder Panesar, Yuegang Zhang, Naziha Alem
-
Publication number: 20190256516Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-A or I-B: wherein the variables are as defined herein.Type: ApplicationFiled: November 15, 2018Publication date: August 22, 2019Inventors: Jean-Damien Charrier, Christopher John Davis, Damien Fraysse, Gorka Etxebarria I Jardi, Simon Pegg, Francoise Pierard, Joanne Pinder, John Studley, Carl Zwicker, Tapan Sanghvi, Michael Waldo, Ales Medek, David Matthew Shaw, Maninder Panesar, Yuegang Zhang, Naziha Alem
-
Patent number: 10160760Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-A or I-B: wherein the variables are as defined herein.Type: GrantFiled: December 5, 2014Date of Patent: December 25, 2018Assignee: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Jean-Damien Charrier, Christopher John Davis, Damien Fraysse, Gorka Etxebarria I Jardi, Simon Pegg, Francoise Pierard, Joanne Pinder, John Studley, Carl Zwicker, Tapan Sanghvi, Michael Waldo, Ales Medek, David Matthew Shaw, Maninder Panesar, Yuegang Zhang, Naziha Alem
-
Publication number: 20180318301Abstract: A pharmaceutical composition comprises: a) 5 wt % to 95 wt % of a HCl salt of Compound (1).xH2O by the weight of the pharmaceutical composition, wherein x is from 0 to 3; and b) 5 wt % to 95 wt % of a filler by the weight of the pharmaceutical composition. Another pharmaceutical composition comprises: a) 1 mg/mL to 20 mg/mL of Compound (1) in water; and b) 0.01 M to 0.1 M of a pharmaceutically acceptable pH modifier. A method of preparing a pharmaceutical composition, comprising providing a mixture of Compound (1) that includes the HCl salt of Compound (1).xH2O and the filler. Another method of preparing a pharmaceutical composition comprises mixing the HCl salt of Compound-(1).xH2O and the pH modifier to form 1 mg/mL to 20 mg/mL of Compound (1) in water. Methods of reducing the amount of influenza viruses, inhibiting the replication of influenza viruses, and treating influenza each independently employ such pharmaceutical compositions.Type: ApplicationFiled: July 16, 2018Publication date: November 8, 2018Inventors: Eric Arthur Simone, Tapan Sanghvi, Alamelu Banda, Katherine Stavropoulos
-
Publication number: 20160250213Abstract: A pharmaceutical composition comprises: a) 5 wt % to 95 wt % of a HCl salt of Compound (1).xH2O by the weight of the pharmaceutical composition, wherein x is from 0 to 3; and b) 5 wt % to 95 wt % of a filler by the weight of the pharmaceutical composition. Another pharmaceutical composition comprises: a) 1 mg/mL to 20 mg/mL of Compound (1) in water; and b) 0.01 M to 0.1 M of a pharmaceutically acceptable pH modifier. A method of preparing a pharmaceutical composition, comprising providing a mixture of Compound (1) that includes the HCl salt of Compound (1).xH2O and the filler. Another method of preparing a pharmaceutical composition comprises mixing the HCl salt of Compound (1).xH2O and the pH modifier to form 1 mg/mL to 20 mg/mL of Compound (1) in water. Methods of reducing the amount of influenza viruses, inhibiting the replication of influenza viruses, and treating influenza each independently employ such pharmaceutical compositions.Type: ApplicationFiled: May 10, 2016Publication date: September 1, 2016Inventors: Eric Arthur Simone, Tapan Sanghvi, Alamelu Banda, Katherine Stavropoulos
-
Publication number: 20150158872Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-A or I-B: wherein the variables are as defined herein.Type: ApplicationFiled: December 5, 2014Publication date: June 11, 2015Inventors: Jean-Damien Charrier, Christopher John Davis, Damien Fraysse, Gorka Etxebarria I Jardi, Simon Pegg, Francoise Pierard, Joanne Pinder, John Studley, Carl Zwicker, Tapan Sanghvi, Michael Waldo, Ales Medek, David Matthew Shaw, Maninder Panesar, Yuegang Zhang, Naziha Alem
-
Publication number: 20150065439Abstract: Described herein are compositions that can include Compound 1 or Form J of Compound 1, or a pharmaceutically acceptable salt of the aforementioned compounds. Also, described herein is a method of treating a HCV infection in a subject that can include administering to the subject a composition that includes Compound 1 or Form J of Compound 1, or a pharmaceutically acceptable salt of the aforementioned compounds.Type: ApplicationFiled: February 27, 2014Publication date: March 5, 2015Applicant: Vertex Pharmaceuticals IncorporatedInventors: Tapan Sanghvi, Kirk Raymond Dinehart
-
Publication number: 20140235705Abstract: A pharmaceutical composition comprises: a) polymorphic form M or tromethamine salt of Compound (1) represented by the following structural formula: and b) a filler. A method of preparing a pharmaceutical composition comprises: providing a mixture of Compound (1) and a filler to form the composition of Compound (1). A method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of the pharmaceutical composition.Type: ApplicationFiled: January 24, 2014Publication date: August 21, 2014Applicant: Vertex Pharmaceuticals IncorporatedInventors: Nicholas Cardoso, Chong-Hui Gu, Peter A. Ojakovo, Tapan Sanghvi, Eric A. Simone, Marinus J. Verwijs
-
Publication number: 20070043070Abstract: Pharmaceutical compositions comprising a salt of a weak base compound of formula: wherein X is hydrogen, halogen, alkyl of less than 7 carbon atoms or alkoxy of less than 7 carbon atoms; n is a positive integer of less than 4; Y is hydrogen, chlorine, nitro, methyl, ethyl or oxy-chloro; R is hydrogen, alkylaminocarbonyl wherein the alkyl group has from 3 to 6 carbon atoms or an alkyl group having from 1 to 8 carbons and R2 is 4-thiazolyl, NHCOOR1 wherein R, is aliphatic hydrocarbon of less than 7 carbon atoms, or an alkyl group of less than 7 carbon atoms; one or more free acids; and optional pharmaceutical additives are provided.Type: ApplicationFiled: March 12, 2004Publication date: February 22, 2007Inventors: Samuel Yalkowsky, Tapan Sanghvi